Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company, which manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 17.35%의 증가율을 기록했습니다.
과대 평가된
회사의 최신 PE은 -4.81로, 최근 3년 기준 높은 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 81.67M주이며, 전 분기 대비 9.25% 감소했습니다.
PRFDX가 보유
스타 투자자 PRFDX이(가) 이 주식 19.68K주를 보유하고 있습니다.
시장 활동 증가
회사는 투자자들의 관심이 높아져, 최근 20일간 회전율이 0.67입니다.